Navigation Links
Osteoporosis Meds Linked to Heart Problem
Date:10/27/2008

Bisphosphonates may up rate of serious atrial fibrillation, review finds,,,,

MONDAY, Oct. 27 (HealthDay News) -- The popular bone-building medications known as bisphosphonates may have a rare, but serious, cardiac side effect.

A review of available research concludes that these medications may increase the risk of atrial fibrillation -- an erratic heart rhythm that can lead to blood clots that may cause heart attacks or strokes.

"In addition to possible gastrointestinal side effects, bisphosphonates can have possible cardiac side effects. For serious cases of atrial fibrillation, there was a significant increase in risk -- about 68 percent," said review lead author Dr. Jennifer Miranda, an internal medicine resident at Jackson Memorial Hospital in Miami.

But Miranda noted that the absolute risk of someone experiencing atrial fibrillation while on these medications was actually quite small, probably around 1 percent to 2 percent.

Miranda was expected to present the findings Monday at the American College of Chest Physicians annual meeting, in Philadelphia.

Bisphosphonates are a class of medications that increase bone mineral density. They are commonly prescribed to treat people with osteoporosis and also for people who have suffered hip fractures. Bisphosphonates may also be used to treat Paget's disease of bone.

This class of medications includes alendronate (Fosamax), zoledronic acid (Reclast), ibandronate (Boniva), risedronate (Actonel), and more.

Although effective, these medications can cause serious side effects in some people. Gastrointestinal side effects, such as nausea, stomach pain, constipation and diarrhea can occur. Of more concern are rare side effects, such as osteonecrosis of the jaw, unusual bone fractures, and severe muscle, bone or joint pain.

The U.S. Food and Drug Administration is reviewing the safety of bisphosphonates, but at this time doesn't recommend any changes in clinical practice.

Miranda's review focused on three studies of bisphosphonates that included data on atrial fibrillation as a side effect. Miranda said the authors reviewed 1,646 studies, but only three included information on atrial fibrillation.

All three studies were randomized, placebo-controlled studies published in the New England Journal of Medicine in 2007, and included more than 16,000 patients. The study populations were quite similar and included postmenopausal women between the ages of 69 and 75 who were taking bisphosphonates for osteoporosis.

The overall difference in incidence of atrial fibrillation wasn't statistically significant between those taking bisphosphonates and placebo. However, when the researchers looked just at serious atrial fibrillation, meaning that it was significant enough to require hospitalization or caused death, they found a 68 percent increased risk for those on bisphosphonates.

Miranda said it's not clear why bisphosphonates might increase the risk of atrial fibrillation.

Dr. Arthur Santora, executive director of clinical research at Merck Research Laboratories, said he was surprised that the current analysis only included three studies. Generally, he said, this type of research will include a dozen or more studies. Merck manufactures Fosamax.

Santora said his researchers have also done a meta-analysis to look at atrial fibrillation, but they included 40 studies, and they didn't find an increase in the risk of serious atrial fibrillation.

"Although this is something you want to track, and we do carefully track atrial fibrillation, there doesn't appear to be an increased risk when you look at the 40 studies we included in our meta-analysis," said Santora.

Santora said that if patients have any concerns about potential side effects, they should talk to their physicians about those concerns.

More information

Here's the latest from the U.S. Food and Drug Administration on bisphosphonates and atrial fibrillation.



SOURCES: Jennifer Miranda, M.D., internal medicine resident, Jackson Memorial Hospital, Miami; Arthur Santora, M.D., executive director, clinical research, Merck Research Laboratories, Whitehouse Station, N.J.; Oct. 27, 2008, presentation, American College of Chest Physicians annual meeting, Philadelphia


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vitamin D Added to FDA Osteoporosis Risk-Reduction Health Claim
2. Retrospective study analyzes expenses of osteoporosis-related fracture over 3 years
3. Simple ultrasound exam may predict osteoporosis risk
4. Figure Skater Peggy Fleming Teams With HealthSaver: Osteoporosis and Bone Health
5. Tufts researcher leads revision of osteoporosis guidelines
6. New study shows sedentary high school girls are at significant risk for future osteoporosis
7. Global study reveals differences in standard of care for osteoporosis across the world
8. National Osteoporosis Foundation Survey Reveals Low Awareness of Bone Health and Risk of Osteoporosis
9. Treating osteoporosis calls for physician, dentist collaboration: ADA Journal
10. Docs Issue Guideline on Screening for Osteoporosis in Men
11. Genes Linked to Osteoporosis Identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Osteoporosis Meds Linked to Heart Problem
(Date:12/10/2016)... ... December 10, 2016 , ... ... Santa are all sources of external stimuli that can put a great deal ... pressure to spread holiday cheer through gifts, food and festive gatherings can lead ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... counseling and aural rehabilitation—provided by audiologists—to remain a critical part of public access ... and Drug Administration (FDA) announced this week that, starting immediately, it ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide ... Columbia as an education tool in the war against teen drug abuse. NCADD ...
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic ... ... analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides ... Japan , Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through 2022. Also, a ...
Breaking Medicine Technology: